The estimated Net Worth of Ann D Rhoads is at least $2.04 Million dollars as of 27 January 2023. Ms. Rhoads owns over 7,500 units of Globus Medical Inc stock worth over $1,585,175 and over the last 14 years she sold GMED stock worth over $40,381. In addition, she makes $416,959 as Independent Director at Globus Medical Inc.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Ms. Rhoads GMED stock SEC Form 4 insiders trading
Ann has made over 9 trades of the Globus Medical Inc stock since 2010, according to the Form 4 filled with the SEC. Most recently she exercised 7,500 units of GMED stock worth $94,425 on 27 January 2023.
The largest trade she's ever made was buying 100,000 units of Globus Medical Inc stock on 21 September 2011 worth over $200,000. On average, Ann trades about 2,949 units every 71 days since 2010. As of 27 January 2023 she still owns at least 22,884 units of Globus Medical Inc stock.
You can see the complete history of Ms. Rhoads stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Ann Rhoads biography
Ann D. Rhoads serves as Independent Director of the Company. Ms. Rhoads currently serves as Chief Financial Officer of Forty Seven, Inc., a clinical-stage company focused on developing checkpoint therapies to activate macrophages in the fight against cancer. Previously, Ms. Rhoads was Executive Vice President and Chief Financial Officer of Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company, from March 2010 through January 2017. From 2000 through the end of 2009, Ms. Rhoads served as the Chief Financial Officer of Premier, Inc., a healthcare supply management company. From 1998 to 2000, she was Vice President, Strategic Initiatives at Premier, Inc., and from 1993 to 1998, she was a Vice President of The Sprout Group, an institutional venture capital firm. Ms. Rhoads holds a B.S. in Finance from the University of Arkansas and an M.B.A. from the Harvard Business School. Ms. Rhoads also serves on the board of directors, as chairman of the audit committee and as a member of the compensation committee of Evoke Pharma, Inc. (NASDAQ: EVOK). Ms. Rhoads also previously served on the board of directors of Iridex Corporation (NASDAQ: IRIX) from 2017 to 2018 and Novellus Systems, Inc. (NASDAQ: NVLS) from 2003 until 2012. Ms. Rhoads’ experience as the chief financial officer of a publicly-traded pharmaceutical company and as a member of the board of directors of a publicly-traded company brings to our Board of Directors and the committees of our Board of Directors valuable financial skills and expertise, which qualify her to serve as an “audit committee financial expert” on our Audit Committee, and significant executive management experience and leadership skills, as well as a strong understanding of corporate governance principles.
What is the salary of Ann Rhoads?
As the Independent Director of Globus Medical Inc, the total compensation of Ann Rhoads at Globus Medical Inc is $416,959. There are 10 executives at Globus Medical Inc getting paid more, with David Demski having the highest compensation of $3,449,790.
How old is Ann Rhoads?
Ann Rhoads is 55, she's been the Independent Director of Globus Medical Inc since 2011. There are 8 older and 9 younger executives at Globus Medical Inc. The oldest executive at Globus Medical Inc is James Tobin, 75, who is the Independent Director.
What's Ann Rhoads's mailing address?
Ann's mailing address filed with the SEC is C/O REPARE THERAPEUTICS INC., , ST-LAURENT, A8, H4S 1Z9.
Insiders trading at Globus Medical Inc
Over the last 12 years, insiders at Globus Medical Inc have traded over $375,265,297 worth of Globus Medical Inc stock and bought 2,005 units worth $99,824 . The most active insiders traders include David C Paul, Kurt Wheeler, and David M Demski. On average, Globus Medical Inc executives and independent directors trade stock every 42 days with the average trade being worth of $11,005,133. The most recent stock trade was executed by Leslie V Norwalk on 11 July 2024, trading 1,000 units of GMED stock currently worth $70,000.
What does Globus Medical Inc do?
globus medical, inc. is a leading musculoskeletal implant manufacturer and is driving significant technological advancements across a complete suite of spinal products. founded in 2003, globus’ single-minded focus on advancing spinal surgery has made it the fastest growing company in the history of orthopedics. globus is driven to utilize superior engineering and technology to achieve pain free, active lives for all patients with spinal disorders. additional information can be accessed at www.globusmedical.com.
What does Globus Medical Inc's logo look like?
Complete history of Ms. Rhoads stock trades at Evoke Pharma Inc, IRIDEX, QuidelOrtho, Zogenix Inc, Globus Medical Inc, Repare Therapeutics, and iTeos Therapeutics
Globus Medical Inc executives and stock owners
Globus Medical Inc executives and other stock owners filed with the SEC include:
-
David Demski,
President, Chief Executive Officer, Director -
David Paul,
Executive Chairman of the Board -
Daniel Scavilla,
Executive Vice President, Chief Commercial Officer -
David M. Demski,
CEO, Pres & Director -
Kelly Huller,
Senior Vice President, General Counsel, Corporate Secretary -
David C. Paul,
Co-Founder & Exec. Chairman -
Daniel T. Scavilla,
Exec. VP, Chief Commercial Officer & Pres of Trauma -
Keith Pfeil,
Chief Financial Officer, Senior Vice President -
Keith W. Pfeil,
Sr. VP & CFO -
Kelly G. Huller Esq.,
Sr. VP & Gen. Counsel -
Ann Rhoads,
Independent Director -
Robert Douglas,
Independent Director -
James Tobin,
Independent Director -
Daniel Lemaitre,
Independent Director -
Steve Zarrilli,
Independent Director -
David Davidar,
Independent Director -
Richard Holifield,
Exec. Officer -
Mike Reeder,
Exec. Officer -
Steven M. Payne,
VP & Controller -
A. Brett Murphy,
Exec. VP of International Sales -
Brian J. Kearns,
Sr. VP of Bus. Devel. & Investor Relations -
John A De Ford,
-
Kurt Wheeler,
Director -
Robert Liptak,
Director -
Steven Payne,
Chief Accounting Officer -
Anthony L Williams,
President -
Stephen T Zarrilli,
-
Leslie V Norwalk,
-
Dan Wolterman,
-
Dan Lemaitre,
-
A Brett Murphy,
Executive VP, US Sales -
Eric Schwartz,
Senior VP and General Counsel -
Sachs & Cogoldman Sachs Gro...,
-
Lifesciences I, L.P.Clarus ...,
-
Sachs Pep 2004 Offshore Hol...,
-
Richard A Baron,
Senior VP and CFO -
Sachs Group Incgoldman Sach...,
-
Sachs Private Equity Partne...,